ALK and neuroblastoma: Therefore, ALK has emerged as a critical player in NB and tractable ‘oncogene’ opening new perspectives into the design and development of gene-targeted therapies for NB and other ALK-driven cancers [8, 10, 11], such as Non-Small-Cell Lung Cancers (NSCLC) [12] and Anaplastic Large-Cell Lymphomas (ALCL) [13] characterized by oncogenic ALK fusion proteins arising from chromosomal translocations.